These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11440980)

  • 1. Role for tissue factor pathway in murine model of vascular remodeling.
    Singh R; Pan S; Mueske CS; Witt T; Kleppe LS; Peterson TE; Slobodova A; Chang JY; Caplice NM; Simari RD
    Circ Res; 2001 Jul; 89(1):71-6. PubMed ID: 11440980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling.
    Singh R; Pan S; Mueske CS; Witt TA; Kleppe LS; Peterson TE; Caplice NM; Simari RD
    Thromb Haemost; 2003 Apr; 89(4):747-51. PubMed ID: 12669131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries.
    Golino P; Cirillo P; Calabro' P; Ragni M; D'Andrea D; Avvedimento EV; Vigorito F; Corcione N; Loffredo F; Chiariello M
    J Am Coll Cardiol; 2001 Aug; 38(2):569-76. PubMed ID: 11499754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis.
    Pan S; Kleppe LS; Witt TA; Mueske CS; Simari RD
    Thromb Haemost; 2004 Sep; 92(3):495-502. PubMed ID: 15351845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries.
    Yin X; Yutani C; Ikeda Y; Enjyoji K; Ishibashi-Ueda H; Yasuda S; Tsukamoto Y; Nonogi H; Kaneda Y; Kato H
    Cardiovasc Res; 2002 Dec; 56(3):454-63. PubMed ID: 12445886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.
    Crawley J; Lupu F; Westmuckett AD; Severs NJ; Kakkar VV; Lupu C
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1362-73. PubMed ID: 10807755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice.
    Westrick RJ; Bodary PF; Xu Z; Shen YC; Broze GJ; Eitzman DT
    Circulation; 2001 Jun; 103(25):3044-6. PubMed ID: 11425765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.
    Caplice NM; Mueske CS; Kleppe LS; Simari RD
    Circulation; 1998 Sep; 98(11):1051-7. PubMed ID: 9736590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.
    Migdalski A; Kotschy M; Jawien A
    Eur J Vasc Endovasc Surg; 2005 Jul; 30(1):41-7. PubMed ID: 15933981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries.
    Atsuchi N; Nishida T; Marutsuka K; Asada Y; Kamikubo Y; Takeshita A; Ueno H
    Circulation; 2001 Jan; 103(4):570-5. PubMed ID: 11157724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.
    Kaikita K; Takeya M; Ogawa H; Suefuji H; Yasue H; Takahashi K
    J Pathol; 1999 Jun; 188(2):180-8. PubMed ID: 10398162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
    Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L
    Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction.
    Steppich B; Mattisek C; Sobczyk D; Kastrati A; Schömig A; Ott I
    Thromb Haemost; 2005 Jan; 93(1):35-9. PubMed ID: 15630488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: a potential therapeutic opportunity for atherosclerotic thrombosis.
    Jiang P; Xue D; Zhang Y; Ye L; Liu Y; Makale M; Kesari S; Edgington TS; Liu C
    Thromb Res; 2014 Apr; 133(4):657-66. PubMed ID: 24485401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
    Shimizu S; Ogawa T; Takezawa K; Tojima I; Kouzaki H; Shimizu T
    Am J Rhinol Allergy; 2015; 29(4):235-42. PubMed ID: 26163243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins.
    Zawadzki C; Susen S; Richard F; Haulon S; Corseaux D; Jeanpierre E; Vincentelli A; Lucas C; Torpier G; Martin A; Van Belle E; Staels B; Jude B
    Atherosclerosis; 2007 Dec; 195(2):e117-25. PubMed ID: 17196206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension.
    White TA; Witt TA; Pan S; Mueske CS; Kleppe LS; Holroyd EW; Champion HC; Simari RD
    Am J Respir Cell Mol Biol; 2010 Jul; 43(1):35-45. PubMed ID: 19648471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor and tissue factor pathway inhibitor: a potential role in pregnancy and obstetric vascular complications?
    Dusse LM; Carvalho Md; Cooper AJ; Lwaleed BA
    Clin Chim Acta; 2006 Oct; 372(1-2):43-6. PubMed ID: 16713593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.